[{"id":"1857c25a-008a-4654-8ea7-f9a19cdb4081","acronym":"","url":"https://clinicaltrials.gov/study/NCT02386501","created_at":"2021-01-18T11:22:29.087Z","updated_at":"2024-07-02T16:36:43.137Z","phase":"Phase 1b","brief_title":"Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors","source_id_and_acronym":"NCT02386501","lead_sponsor":"Advaxis, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lovaxin B (diznalimgene lisbac)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 04/01/2017","primary_completion_date":" 04/01/2017","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2020-07-16"}]